Background
Skin cutaneous melanoma (SKCM) accounts for only 2% of total skin cancers. However, due to its high degree of malignancy and invasiveness, it causes over 72% of deaths in skin carcinoma [
1]. The incidence of cutaneous malignant melanoma continues to increase annually [
2]. Melanoma has become a serious public health problem, bringing great economic burden for society [
3]. It is well known that melanoma is associated with multiple risk factors especially the sun exposure [
4]. The general progression models of SKCM are from melanocyte to melanoma in situ, to invasive melanoma [
5]. However, extensive research has explored the mechanism of recurrence and metastasis, the tumorigenesis of cutaneous melanoma remains unclear.
In the present study, we analyzed the differentially expressed genes (DEGs) between primary melanoma and normal skin to explore the potential tumorigenesis mechanism of SKCM. Our results mainly identified several chemokine family members (CXCL9, CXCL10, CXCL13, CCL4, CCL5) which were found related to better overall survival (OS) in SKCM patients. Chemokine family members are a group of low-molecular weight cytokines which were involved in many biological processes including angiogenesis, tumor development and metastasis, and the migration of leukocytes [
6,
7]. In addition, we found that their expression levels were positively associated with infiltration of immune cells (CD4
+T, CD8
+T, B-cell, macrophages, neutrophils, dendritic cells) and tumor infiltrating lymphocytes (TILs). These immune infiltration cells play important roles in tumor microenvironment and can directly or indirectly regulate tumor immunity and modulate tumor immunological for anti-tumor effects [
7,
8]. Therefore, our results may identify several immune-related biomarkers that may serve to guide SKCM therapy.
Discussion
Skin is the largest organ of human beings. There are about 1500 melanocytes in human epidermis per square millimeter, equivalent to nearly 3 billion melanocytes in an ordinary human skin [
23]. The incidence of SKCM continues to increase every year. Once melanoma spreads through the dermis, the prognosis is poor and melanoma is not projected to reduce the death rate in the next few years [
24]. A series of therapeutic methods, such as radiotherapies, chemotherapies, targeted therapies and immunotherapies have enhanced advanced patient survival [
25]. However, many patients that are being administered these therapies demonstrate a low durable response, drug resistance and poor prognosis [
26]. Therefore, more therapeutic targets and prognostic biomarkers must be identified.
In our study, 308 DEGs were identified between primary SKCM and normal skin, and the functional annotation indicated that inflammatory response and immune response were closely associated with SKCM tumorigenesis. KEGG pathways in hub genes included IL-10 signaling, chemokine receptors bind chemokine signaling and peptide ligand-binding receptors. STAT3 is essential for the action of IL-10 and IL-6. IL-6 plays a central role in melanoma development and enhances the IL-10 production via STAT3-dependent signaling [
27]. IL-6,10/JAK-STAT3 pathways are found in many carcinomas, and their hyperactivation was generally related to unfavorable clinical prognosis [
28]. IL-6 and IL-10 create a favorable environment to support tumorigenesis by increasing the cancer cell proliferation, angiogenesis, metastasis and contribute to enhancing the immune suppression [
28]. Smith et al. found that IL-10 directly inhibits CD8
+T cell function by enhancing N-Glycan branching to decrease antigen sensitivity [
29]. However, chemokine and its receptors usually attract immune cells such as CD8
+T cell and NKs in the tumor microenvironment for immune activation [
30]. Apparently, these two pathways play opposite roles in tumor formation, and the tumorigenesis of SKCM may be related to their abnormality.
Moreover, SKCM patients with high expression of five chemokines (CXCL9, CXCL10, CXCL13, CCL4, CCL5) were associated with better OS. While high levels of NMU and GAL showed poor prognosis. In addition, we found that the high expression of CXCL9, CXCL10, CXCL13, CCL4 and CCL5 were related to better outcomes in Breslow depth, Clark level, T-stages. IHC results from FAHSU cohort verified that CXCL9, CXCL10, CXCL13, CCL4, CCL5 were significantly over-expressed in SKCM tissues. All of the results suggested that chemokines members (CXCL9, CXCL10, CXCL13, CCL4, CCL5) and NMU, GAL were important biomarkers in SKCM tumorigenesis, progression and prognosis.
Chemokines are chemotactic cytokines mediating the migration and localization of immune cells [
31]. C–X–C motif ligand 9,10,13 (CXCL9, CXCL10, CXCL13) belong to CXC family chemokine. They are predominantly expressed by immune cells such as macrophages and T cells. CXCL9, CXCL10 exert their function through binding to C-X-C motif receptor CXCR3 that was highly expressed on the activated T cells [
30]. Research shows that CD8
+T cell infiltration is CXCR3 dependent [
32]. CD8
+T cell plays important role in tumor microenvironment, which inhibits the proliferation and metastasis of tumor cells. A recent research found that the CXCL10-CXCR3 axis may relate to melanoma brain metastasis [
33]. Additionally, the CXCR3 ligands enhanced the response rates to immune checkpoint blockade (anti-PD-1, anti-CTLA-4) by recruiting T cells [
34]. These results reveal the importance of manipulating this axis, which provide us opportunities to manipulate chemokine expression for tumor therapy and prevention.
C–C motif ligand CCL4, CCL5 belong to CC family chemokine. CCL4, CCL5, CXCL9, CXCL10 were confirmed to be preferentially expressed in tumors that contained T cells [
35]. This suggests that CCL4, 5 and CXCL9,10 may act in the same pathway in T-cell recruitment. The experimental results carried out by Michelle H et al. showed that expression of CXCR3 ligands and CCL5 in chemotherapy tumors did lead to a synergistic increase in T-cell infiltration [
36]. It is also been reported that CCL5 released by tumor cells acts its function via paracrine signaling to attract NKs to the tumor bed [
37]. Taken together, we assumed that CCL4 and CCL5 may be potent biomarkers and targets for melanoma.
Then, we conducted correlation analysis, and high correlation coefficients were observed among chemokine members (CXCL9, CXCL10, CXCL13, CCL4, CCL5) as expected, suggesting that these chemokines play a synergistic role in the tumorigenesis and progression of SKCM. We also explored the transcription factors for these chemokines, and found that IRF7, RELA, NFKB1, IRF3 and IRF1 may be key transcription factors in the regulation of CCL4, CCL5 and CXCL10. RELA phosphorylation is involved in multiple inflammatory diseases and cancer progression by regulating NF-κB signaling [
38]. NFKB1 is an suppressor of inflammation and cancer, which plays an inhibitory role in the occurrence and progression by reducing the abnormal activation of NF-κB signal pathway [
39]. IRF family regulates type-I IFN system for anti-tumor immunity through promoting differentiation of B cells, inducing differentiation of naive T cells to effector CD4
+ or CD8
+T cells and driving the expression of MHC class I and II [
40]. Our results may provide evidence about the complicated correlation among SKCM, chemokines, type-I IFN system and the NF-κB signaling pathway.
In addition, the expressions of CXCL9, CXCL10, CXCL13, CCL4 and CCL5 were positively correlated with six immune cell infiltration (B cells, CD8
+T cells, CD4
+T cells, macrophages, neutrophils, dendritic cells) and 28 types of TILs. However, NMU and GAL were not significantly correlated with infiltration of immune cells and TILs. Previous studies suggested that high levels of immune cell infiltration are associated with favorable outcomes [
41]. It was similar to our results that increasing levels of B cells, CD8
+T cells, neutrophils, dendritic cells were related to longer survival time in SKCM patients. A novel study based on thousands of melanoma patients found that the degree of lymphocyte infiltration was an independent prognosticator of disease-free survival (DFS), revealing that a lesser level was associated with a reduced DFS [
42]. What’s more, we predicted drug-gene interaction pairs between hub genes and 69 drugs, indicating that our results may reveal immune-related targets for SKCM therapy.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.